title: [Neoadjuvant chemotherapy for esophageal cancer by administration of nedaplatin alone].
abstract: The possibility of safe implementation of neoadjuvant chemotherapy using nedaplatin (254-S) was investigated with the aim of improving the therapeutic results in advanced esophageal cancer patients. The subjects had usually undergone two courses of 254-S, 80 or 100 mg/m2, preoperatively, at intervals of 4 weeks. After chemotherapy, responses were evaluated, and resection was undertaken 4 weeks after the final administration. The subjects were 10 patients with untreated esophageal cancer. As a result of evaluation of responses of main lesions to chemotherapy, a partial response (PR) was observed in 3 patients, and a minor response 3, showing an efficacy rate of 30%. Pathological findings before treatment were determined by staining of a cell cycle marker (Ki-67). The 3 patients who were evaluated as PR (clinical efficacy) showed high rates of positivity for Ki-67 of 47.4%, 52.7%, and 86%, respectively. There were no serious complications and no death related to operation. The observations suggested that 254-S, which has little or no side effects including nephrotoxicity, can become the standard remedy for esophageal cancer instead of CDDP in future.
authors.affiliation: First Dept. of Surgery, Asahikawa Medical College.
authors.forename: S
authors.initials: S
authors.lastname: Hirata
authors.forename: E
authors.initials: E
authors.lastname: Yatsuyanagi
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Sugimoto
authors.forename: S
authors.initials: S
authors.lastname: Kosiko
authors.forename: T
authors.initials: T
authors.lastname: Kokubo
authors.forename: Y
authors.initials: Y
authors.lastname: Atsuta
authors.forename: T
authors.initials: T
authors.lastname: Sasajima
authors.forename: N
authors.initials: N
authors.lastname: Miyokawa
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002453:Cell Cycle; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D011300:Preoperative Care; D016159:Tumor Suppressor Protein p53 / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D009944:Organoplatinum Compounds; D016159:Tumor Suppressor Protein p53; C053989:nedaplatin